检索结果-南通市图书馆

Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease(GCKD)cohort

引用

Bone Research 2023年第4期11卷 764-771页

作者： Katharina Charlotte Reimer Jennifer Nadal Heike Meiselbach matthias Schmid Ulla T.Schultheiss Fruzsina Kotsis Helena Stockmann Nele Friedrich matthias nauck Vera Krane Kai-Uwe Eckardt Markus P.Schneider Rafael Kramann Jürgen Floege Turgay Saritas Department of Nephrology Rheumatologyand Clinical ImmunologyUniversity Hospital RWTH AachenAachenGermany Institute of Experimental Medicine and Systems Biology RWTH Aachen UniversityAachenGermany Institute for Cell and Tumor Biology RWTH Aachen UniversityAachenGermany Institute of Medical Biometry Informatics and EpidemiologyUniversity Hospital of BonnBonnGermany Department of Nephrology and Hypertension University of Erlangen-NürnbergErlangenGermany Institute of Genetic Epidemiology Faculty of Medicine and Medical Center-University of FreiburgFreiburgGermany Department of Medicine IV-Nephrology and Primary Care Faculty of Medicine and Medical Center-University of FreiburgFreiburgGermany Department of Nephrology and Medical Intensive Care Charité-Universitätsmedizin BerlinBerlinGermany Department of Nephrology University Medical Center RegensburgRegensburgGermany Institute of Clinical Chemistry and Laboratory Medicine University Medicine GreifswaldGreifswaldGermany DZHK(German Centre for Cardiovascular Research) Partner Site GreifswaldUniversity MedicineGreifswaldGermany Department of Medicine I Division of NephrologyUniversity Hospital WürzburgWürzburgGermany

Mineral and bone disorder(MBD)in chronic kidney disease(CKD)is tightly linked to cardiovascular disease(CVD).In this study,we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular(CV)outcomes and *** 5217 participants of the German CKD(GCKD)study enrolled with an estimated glomerular filtration rate(eG FR)between 30–60 mL·min-1 per 1.73 m2 or overt proteinuria,serum osteoprotegerin(OPG),C-terminal fibroblast growth factor-23(FGF23),intact parathyroid hormone(iP TH),bone alkaline phosphatase(BAP),cross-linked C-telopeptide of type 1 collagen(CTX1),procollagen 1intact N-terminal propeptide(P1NP),phosphate,calcium,and 25-OH vitamin D were measured at *** with missing values among these parameters(n=971)were excluded,leaving a total of 4246 participants for *** a median follow-up of6.5 years,387 non-CV deaths,173 CV deaths,645 nonfatal major adverse CV events(MACEs)and 368 hospitalizations for congestive heart failure(CHF)were *** and FGF23 were associated with all outcomes,with the highest hazard ratios(HRs)for *** the final Cox regression model,adjusted for CV risk factors,including kidney function and all other investigated biomarkers,each standard deviation increase in OPG was associated with non-CV death(HR 1.76,95%CI:1.35–2.30),CV death(HR 2.18,95%CI:1.50–3.16),MACE(HR 1.38,95%CI:1.12–1.71)and hospitalization for CHF(HR 2.05,95%CI:1.56–2.69).Out of the nine biomarkers examined,stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.

关键词： Kidney cardiovascular vitamin

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Benefit of Growth Hormone Replacement in Adults Older than 60 Years

引用

Open Journal of Endocrine and Metabolic Diseases 2013年第3期3卷 166-178页

作者： Kristin Arp Christian Schwahn Nele Friedrich Thomas Kohlmann Jorn Moock Maria Koltowska-Haggstrom matthias nauck Michael Buchfelder Henri Wallaschofski Christin Spielhagen Institute of Clinical Chemistry and Laboratory Medicine University Medicine GreifswaldGreifswaldGermany Community Medicine University Medicine GreifswaldGreifswaldGermany KIGS/KIMS/ACROSTUDY Medical Outcomes Pfizer Endocrine CareSollentunaSweden Department of Neurosurgery University of ErlangenErlangenGermany

Objective: Benefits of replacement therapy in growth hormone deficiency (GHD) are well documented in younger and middle-aged patients. The aim of our investigation was to prove the benefit of GH replacement for patients older than 60 years especially in terms of health-related quality of life (HRQoL) of age as well. Design: Data of 743 consecutively recruited patients (394 men, 349 women) with GHD aged 20 - 49 (n = 606) and 60 - 69 (n = 137) years enrolled from KIMS Germany (Pfizer International Metabolic Database) were compared. Treatment effects over the 12 months dose-finding and the subsequent phase up to three years were analysed using mixed models. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI) at baseline and at last visit were studied. HRQoL was assessed using the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA). Results: For both age groups and genders the IGF-I level and standardized IGF-I increased over the dose-finding phase. In women, the overall QoL-AGHDA score at the baseline examination was 8.7 (95% CI: 7.7 - 9.7) and decreased to 6.3 (95% CI: 5.1 - 7.6) at the end of the dose-finding phase (p < 0.001). In men, the corresponding values were 8.8 (95% CI: 7.8 - 9.8) and 6.4 (95% CI: 5.1 - 7.6;p < 0.001) without differences between the age groups. The therapy benefit for elderly was supported by the non-impairment after the dose-finding phase. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were detected, whereas an increase in BMI did not differ between age groups. Conclusion: We could show positive effects of GH replacement on HRQoL in patients older than 60 years of age. Therefore, GH replacement should be considered in elderly GHD adults without difference compared to younger age groups.

关键词： Growth Hormone Deficiency Quality of Life Growth Hormone IGF-I

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Influence of gastric inhibitory polypeptide on pentagastrinstimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

引用

World Journal of Gastroenterology 2006年第12期12卷 1874-1880页

作者： Juris J Meier Michael A nauck Bartholomaeus Kask Jens J Hoist Carolyn F Deacon Wolfgang E Schmidt Baptist Gallwitz Department of Medicine I St. Josef-HospitalRuhr-University Bochum Germany Diabeteszentrum Bad Lauterberg Germany Department of Medical Physiology The Panum Institute University of Copenhagen Denmark Department of Medicine IV Eberhard-Karls- University Ttibingen Germany

AIM： Gastric inhibitory polypeptide is secreted from intestinal K-cells in response to nutrient ingestion and acts as an incretin hormone in human physiology. While animal experiments suggested a role for GIP as an inhibitor of gastric secretion, the GIP effects on gastric acid output in humans are still controversial. METHODS： Pentagastrin was administered at an infusion rate of 1 μg . kg^-1 . h^-1 over 300 min in 8 patients with type 2 diabetes （2 female, 6 male, 54± 10 years, BMI 30.5 ± 2.2 kg/m^2; no history of autonomic neuropathy） and 8 healthy subjects （2/6, 46 ± 6 years., 28.9 ± 5.3 kg/ m^2）. A hyperglycaemic clamp （140 mg/dl） was performed over 240 min. Placebo, GIP at a physiological dose （1 pmol . kg^-1 . min^-1）, and GIP at a pharmacological dose （4 mol . kg^-1 . min^-1） were administered over 60 min each. Boluses of placebo, 20 pmol GIP/kg, and 80 pmol GIP/kg were injected intravenously at the beginning of each infusion period, respectively. Gastric volume, acid and chloride output were analysed in 15-min intervals. Capillary and venous blood samples were drawn for the determination of glucose and total GIP. Statistics were carried out by repeated-measures ANOVA and one-way ANOVA. RESULTS： Plasma glucose concentrations during the hyperglycaemic clamp experiments were not different between patients with type 2 diabetes and controls. Steady-state GIP plasma levels were 61 ±8 and 79 ± 12 pmol/I during the low-dose and 327±35 and 327± 17 pmol/I during the high-dose infusion of GIP, in healthy control subjects and in patients with type 2 diabetes, respectively （P= 0.23 and p 0.99）. Pentagastrin markedly increased gastric acid and chloride secretion （P〈 0.001）. There were no significant differences in the rates of gastric acid or chloride output between the experimental periods with placebo or any dose of GIP. The temporal patterns of gastric acid and chloride secretion were similar in patients with type 2 diabetes and healthy controls （P= 0.86 and P= 0.6

关键词： Gastric inhibitory polypeptide Gastric acid secretion Type 2 diabetes Hyperglycemic clamp Pentagastrin-stimulated acid secretion

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

利拉鲁肽对HbA1c和体重的改善与糖尿病病程的关系

利拉鲁肽对HbA1c和体重的改善与糖尿病病程的关系

引用

中华医学会第十二次全国内分泌学学术会议

作者： Jochen Seufert Timothy Bailey Claus Bo Svendsen Morten Donsmark Michael nauck University Hospital of Freiburg FreiburgGermany

目的:在利拉鲁肽3期研究项目(Liraglutide Effect andAction in Diabetes,LEAD)中已证实利拉鲁肽在2型糖尿病的持续治疗过程中的临床有效性,然而基线时的糖尿病病程在其中的影响并不清楚。这里对7个临床试验(LEAD-1至LEAD-6和Lira-DPP-...

目的:在利拉鲁肽3期研究项目(Liraglutide Effect andAction in Diabetes,LEAD)中已证实利拉鲁肽在2型糖尿病的持续治疗过程中的临床有效性,然而基线时的糖尿病病程在其中的影响并不清楚。这里对7个临床试验(LEAD-1至LEAD-6和Lira-DPP-4i(利拉鲁肽与DPP-4抑制剂的

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

基线体质指数不影响利拉鲁肽在2型糖尿病患者中降低HbA1c的效应

基线体质指数不影响利拉鲁肽在2型糖尿病患者中降低HbA1c的效应

引用

中华医学会第十二次全国内分泌学学术会议

作者： E Montanya V Fonseca S Colagiuri L Blonde Morten Donsmark Claus Bo Svendsen M nauck Hospital Universitari Bellvitge-IDIBELL BarcelonaSpain Tulane University Medical School TulaneNew OrleansLAUSA Boden Institute of Obesity NutritionExercise and Eating DisordersSydneyAustralia Ochsner Medical Center New OrleansLAUSA Novo Nordisk A/S SoborgDenmark Diabeteszentrum Bad LauterbergGermany

目的:利拉鲁肽3期研究项目(Liraglutide Effect andAction in Diabetes,LEAD)的试验结果表明1.2 mg或1.8mg利拉鲁肽治疗2型糖尿病患者可以有效改善血糖控制并减轻体重。然而,这些试验没有研究利拉鲁肽降低血糖的作用是否依赖于患者的基...

目的:利拉鲁肽3期研究项目(Liraglutide Effect andAction in Diabetes,LEAD)的试验结果表明1.2 mg或1.8mg利拉鲁肽治疗2型糖尿病患者可以有效改善血糖控制并减轻体重。然而,这些试验没有研究利拉鲁肽降低血糖的作用是否依赖于患者的基线体质指数(BMI)水平。

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

根据β细胞数量分层,利拉鲁肽1天1次治疗均可比对照药获得更好的血糖控制

根据β细胞数量分层,利拉鲁肽1天1次治疗均可比对照药获得更好的...

引用

中华医学会糖尿病学分会第十六次全国学术会议

作者：罗小夫 J.MEIER T.VILSBФL M.DONSMARK H.HARTVIG M.nauck St.Josef Hospital BochumGermany Gentofte Hospital CopenhagenDenmark Novo Nordisk A/S CopenhagenDenmark Diabeteszentrum Bad LauterbergimHarzGermany

目的血糖控制与人体胰腺β细胞数量密切相关。近期一项研究显示,对于有和无T2DM的患者,C肽:空腹血糖(FPG)比值是更好的胰腺β细胞面积(对β细胞数量的一种估计)的预测指标,优于稳态模型评估(HOMA)指数等指标。这项分析在不同估计残余β...

目的血糖控制与人体胰腺β细胞数量密切相关。近期一项研究显示,对于有和无T2DM的患者,C肽:空腹血糖(FPG)比值是更好的胰腺β细胞面积(对β细胞数量的一种估计)的预测指标,优于稳态模型评估(HOMA)指数等指标。这项分析在不同估计残余β细胞数量的T2DM患者中,比较了每日1次(OD)人胰高糖素样肽(GLP)-1类似物利拉鲁肽(LIRA)和其他降糖药的血糖控制疗效。

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

LEAD-6试验结果:利拉鲁肽治疗后抗体生成的发生率和抗体水平均低于艾塞那肽

LEAD-6试验结果:利拉鲁肽治疗后抗体生成的发生率和抗体水平均低...

引用

中华医学会第十次全国内分泌学学术会议

作者： J.BUSE E.MONTANYA G.SESTI J.BRETT H.SOLBERG J.ROSENSTOCK M.nauck J.HOLST University of North Carolina School of Medicine Chapel HillNCUSA 100020

目的:抗GLP-1受体激动剂的抗体形成后理论上可以通过中和该药物甚至天然GLP-1而减弱药效。LEAD-6是一项为期26周的临床试验,比较利拉鲁肽与艾塞那肽,两组患者均联合使用二甲双胍和/或磺脲类药物。其后进入52周的延长期试验,原使用艾塞...

目的:抗GLP-1受体激动剂的抗体形成后理论上可以通过中和该药物甚至天然GLP-1而减弱药效。LEAD-6是一项为期26周的临床试验,比较利拉鲁肽与艾塞那肽,两组患者均联合使用二甲双胍和/或磺脲类药物。其后进入52周的延长期试验,原使用艾塞那肽的患者改用利拉鲁肽。本研究检测了在LEAD一6以及延长期试验中利拉鲁肽和艾塞那肽抗体的情况。

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

针刺可减轻结肠镜检查时疼痛

引用

上海针灸杂志 1992年第2期 44-44页

作者： C-K.Li M.nauck 罗宗锐

36位病人(男性18人,女性18人),平均年龄51岁(21～76),在做结肠镜检查前进行针刺(穴位:两侧合谷、内关、足三里、公孙),无针刺组和仿针刺组预料不会解痛.在结肠镜检查时用视觉模拟计算机标度(visual analog scale)衡量平均痛觉敏感性.针... 详细信息

36位病人(男性18人,女性18人),平均年龄51岁(21～76),在做结肠镜检查前进行针刺(穴位:两侧合谷、内关、足三里、公孙),无针刺组和仿针刺组预料不会解痛.在结肠镜检查时用视觉模拟计算机标度(visual analog scale)衡量平均痛觉敏感性.针刺组12位患者的平均痛觉敏感性显著低于(1.4±0.4)(P=0.003)无针刺组(n=12;2.7±0.3)或仿针刺组(n=12;3.0±0.3)。此外,给针刺组患者的镇痛剂或镇静剂(镇

关键词：针刺患者病人结肠镜检查镇痛剂

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

MRI与同日CT对慢性阻塞性肺疾病表型分类的一致性评估:一项多中心试验

引用

国际医学放射学杂志 2024年第6期 743页

作者： S.nauck M.Pohl B.J.Jobst C.Melzig H.Meredig O.Weinheimer 王竹山

摘要目的本项前瞻性多中心研究旨在评估肺部MRI和CT在慢性阻塞性肺疾病(COPD)病人表型分类(气道疾病和肺气肿)方面的一致性。方法共纳入15个中心的601例

关键词：

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：